Novartis previously signed an agreement with CellforCure in July to produce CAR-T cell therapies including Kymriah (tisagenlecleucel) – which was the first CAR-T cell therapy approved by the FDA ...

Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

Senator asks Novartis to explain its payments to Cohen, noting FDA approval of cancer drug Novartis made $1.2 million in payments to Cohen's firm during the time that the FDA was deciding whether ...

Of the seven medications authorized for use worldwide, Kymriah from Swiss pharmaceutical corporation Novartis is the only one permitted for use in Korea. Domestic patients treated with Kymriah now ...

The first CAR-T therapy approved by the Food and Drug Administration was Kymriah, made by Novartis, in 2017 for the treatment of pediatric acute lymphoblastic leukemia. A handful more have since ...

Update (September 5): Novartis struck a deal with the UK’s National Health Service to accelerate the delivery of Kymriah to young leukemia patients not responding to other treatments, Reuters reports.

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

Indian pharma eyes anticancer research investment as drug innovation to propel future growth: Nandita Vijayasimha, Bengaluru Wednesday, February 5, 2025, 08:00 Hrs [IST] Indian ph ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.